Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kyotorphin is an endogenous opioid analgesic dipeptide (L-tyrosyl-L-arginine) first isolated from the bovine brain in 1979. It is primarily known for its antinociceptive properties, which it exerts not by direct binding to opioid receptors, but by stimulating the release of Met-enkephalin in the brain and spinal cord. Kyotorphin acts through a specific G protein-coupled receptor (the kyotorphin receptor) that mediates the activation of phospholipase C and inhibition of adenylyl cyclase via Gi proteins. Beyond its role in pain modulation, research has explored its potential as a neuroprotective agent in Alzheimer's disease models, an anti-inflammatory modulator, and a precursor for antimicrobial derivatives. It is unevenly distributed in the brain, with high concentrations in regions associated with the pain pathway, such as the cerebral cortex, midbrain, and medulla oblongata.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kyotorphin.